Please login to the form below

Not currently logged in
Email:
Password:

Medigene

This page shows the latest Medigene news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

Daily Brief: GDPR and NHS Opt Out Day, BioMarin's new rare disease approval and more

It's not just the GDPR's big day, plus news from Medigene and Pfizer. ... We are grateful for this strong demonstration of confidence in Medigene as a global leader in T cell immunology.".

Latest news

  • Medigene buys cancer vaccine start-up Medigene buys cancer vaccine start-up

    Medigene buys cancer vaccine start-up. Acquires Trianta to boost immuno-oncology business. ... The new Medigene will combine proprietary immunotherapy platforms with late stage drug candidates and a marketed product," said Medigene chief executive Frank

  • CMPT announces CEO and loan investment

    He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji

  • Astellas acquires European rights for Eligard

    Previously, Astellas was MediGene's European marketing partner for Eligard, having acquired these rights from TOLMAR Therapeutics in 2001. ... MediGene will also receive single-digit royalties on future net European product sales.

  • A competitive edge

    Haemophilus infections, hepatitis B. India. Polyphenon E . Veregen (Medigene AG). Genital warts .

  • Pharma news in brief

    At the outset of marketing, MediGene will receive a milestone payment from its marketing partner Astellas Pharma Europe. ... MediGene also receives royalties on the sales of Eligard. Teva launches generic Wellbutrin Xl tablets.

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Firstly reviewing the licences and collaborations:. bluebird bio gained access to Medigene's T cell receptor platform for the development of TCR cancer immunotherapy candidates for four indications (not disclosed) Bluebird ... 1, 695. Medigene /Bluebird

  • Pharma deals during January 2014 Pharma deals during January 2014

    An interesting biotech:biotech deal was the acquisition of Trianta by Medigene, although the value at $8m does not feature in our top table.

  • Interview: Yoshihiko Hatanaka, CEO and president, Astellas Interview: Yoshihiko Hatanaka, CEO and president, Astellas

    It acquired the European marketing rights to Eligard, a prostate cancer drug, from MediGene via this route and is co-developing a compound for acute myeloid leukaemia with Ambit.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Industry round up: appointments Industry round up: appointments

    His career history has seen him serve as interim chief financial officer and chief operating officer of Medigene, a German biotech company.

  • Dave Lemus joins Proteros as an executive board member Dave Lemus joins Proteros as an executive board member

    Dave Lemus joins Proteros as an executive board member. He joins the German biotech’s board from Medigene. ... Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an

  • Apeiron bolsters management board Apeiron bolsters management board

    During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

  • Lanthio Pharma bolsters management team Lanthio Pharma bolsters management team

    Prior to this, he held the role of chief medical and development officer at both Medigene and TopoTarget, and served as a medical director at MorphoSys.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics